As controversy heightens around potential treatments for COVID-19, government agencies and drug manufacturers are scrambling to find up-to-date information regarding authorized use.
Although ketamine clinics may provide a roadmap for psilocybin clinics, a key difference is that psilocybin remains a Schedule I drug under the Controlled Substances Act.